Encorafenib/binimetinib/nivolumab combo improves PFS in BRAF-mutant melanoma brain metastases

Enhanced pathologic response with neoadjuvant pembrolizumab plus vidutolimod in high-risk resectable melanoma

Nivolumab plus ipilimumab vs gemcitabine-carboplatin in cisplatin-ineligible metastatic urothelial carcinoma

Tumour microenvironment and circulating biomarkers predict response to immunotherapy in advanced RCC

QoL maintained with sasanlimab plus BCG in high-risk, BCG-naive NMIBC

Upfront modified FOLFOXIRI plus panitumumab improves OS in RAS/BRAF wild-type mCRC

Long-term infusion of dinutuximab beta improves survival in high-risk neuroblastoma

Trastuzumab deruxtecan plus pertuzumab may delay cancer growth for some HER2-positive advanced breast cancers

Cemiplimab reduces disease recurrence as adjuvant therapy for cutaneous squamous cell carcinoma

Trastuzumab deruxtecan benefit for some advanced gastric cancers

HER2-positive breast cancer: Predicting pCR from clinicopathologic variables and genomic testing

Making immune check point inhibitors for lung cancer cost-effective in LMICs